Our experience and innovation provide the correct solutions
Alfa CDMO's offers a series of integrated CDO for mAb products from antibody humanization, cell line development, to analytic development, quality standard establishment, and stability studies.
The establishment of a stable cell line is essential for large scale antibody drug production. Alfa CDMO has experience with a broad range of mammalian expression platforms. CHO cell is primarily used for cell line development and a proprietary line has been established. These cell line platforms offer high titers and efficiency to meet challenging timelines. Relying on extensive experience and advanced equipment, Alfa CDMO provides high-quality service in accordance with your specific needs.
Alfa CDMO provides upstream process service with various cell culture systems and advanced in-process analytical technologies, as well as extensive experience on various CHO cell types.
Alfa CDMO offers downstream process services for a variety of biologics including monoclonal antibodies, recombinant proteins. The downstream process secures removal of process and product related impurities, high recovery.
Alfa CDMO is the one of the leading companies for ADC drug development in the world which provides technically challenging service from development to commercial production including both payload and ADC. Additionally, innovative linker technologies are implemented to improve therapeutic window and decrease nonspecific cytotoxicity. The first-class service can significantly speed up ADC drug development process.
Alfa CDMO applies state-of-the-art instrument to perform comprehensive characterization on biologics and linker/payload Analytical method development and optimization/improvement and validation of monoclonal antibody, recombinant protein, complex glycoprotein and ADC.
Small molecule project research: structure characterization, purity analysis, bioactivity analysis, etc.